Immunome, Inc. (NASDAQ:IMNM) Receives Average Rating of “Buy” from Analysts

Immunome, Inc. (NASDAQ:IMNM) has been given an average rating of “Buy” by the seven research firms that are presently covering the firm, MarketBeat reports. Seven analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokerages that have covered the stock in the last year is $28.83.

Several research analysts have issued reports on the stock. Piper Sandler decreased their target price on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a report on Thursday, November 14th. Wedbush reissued an “outperform” rating and set a $33.00 price objective on shares of Immunome in a report on Friday, October 25th. Finally, Stephens initiated coverage on shares of Immunome in a report on Friday, November 8th. They set an “overweight” rating and a $30.00 price objective for the company.

Immunome Stock Performance

Shares of Immunome stock opened at $11.15 on Tuesday. The stock has a market capitalization of $695.98 million, a PE ratio of -1.37 and a beta of 1.82. Immunome has a 52-week low of $6.93 and a 52-week high of $30.96. The company has a 50-day simple moving average of $12.49 and a two-hundred day simple moving average of $13.55.

Insiders Place Their Bets

In other news, CEO Clay B. Siegall purchased 66,057 shares of the company’s stock in a transaction on Thursday, November 21st. The stock was acquired at an average cost of $9.54 per share, for a total transaction of $630,183.78. Following the completion of the transaction, the chief executive officer now directly owns 485,693 shares in the company, valued at $4,633,511.22. This trade represents a 15.74 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CTO Philip Tsai purchased 21,000 shares of the company’s stock in a transaction on Thursday, November 21st. The stock was purchased at an average price of $9.43 per share, with a total value of $198,030.00. Following the completion of the transaction, the chief technology officer now owns 21,000 shares of the company’s stock, valued at approximately $198,030. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 102,862 shares of company stock worth $978,045 over the last three months. 8.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Immunome

Several hedge funds have recently modified their holdings of IMNM. Quest Partners LLC purchased a new stake in Immunome during the second quarter valued at $81,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Immunome during the second quarter valued at $97,000. Arizona State Retirement System raised its stake in Immunome by 9.2% during the second quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock valued at $131,000 after purchasing an additional 918 shares in the last quarter. Intech Investment Management LLC purchased a new stake in Immunome during the third quarter valued at $219,000. Finally, AQR Capital Management LLC raised its stake in Immunome by 34.6% during the second quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock valued at $194,000 after purchasing an additional 4,129 shares in the last quarter. Hedge funds and other institutional investors own 44.58% of the company’s stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.